Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

Phase 2 Recruiting 120 enrolled Chang Gung Memorial Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the clinical outcomes of Lenvatinib treatment alone or Lenvatinib + ADI-PEG20 combination treatment in advanced HCC patients with BCLC stage C.

Timeline

Start: 2023-12-01
Primary completion: 2026-07-23
Completion: 2026-07-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pegargiminase	Protein / enzyme biologic	—	—

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

Summary

Timeline

Drugs

Indications